Prospective assessment of systemic microRNAs as markers of response to neoadjuvant chemotherapy in breast cancer

Andrew McGuire; Maire Caitlin Casey; Ronan M. Waldron; Helen Heneghan; Olga Kalinina; Emma Holian; Ailbhe McDermott; Aoife J. Lowery; John Newell; Róisín M. Dwyer; Nicola Miller; Maccon Keane; James A.L. Brown; Michael J. Kerin

doi:10.3390/cancers12071820

Prospective assessment of systemic microRNAs as markers of response to neoadjuvant chemotherapy in breast cancer

Andrew McGuire, Maire Caitlin Casey, Ronan M. Waldron, Helen Heneghan, Olga Kalinina, Emma Holian, Ailbhe McDermott, Aoife J. Lowery, John Newell, Róisín M. Dwyer, Nicola Miller, Maccon Keane, James A.L. Brown, Michael J. Kerin

Research output: Contribution to journal › Article › peer-review

Abstract

Neoadjuvant chemotherapy (NACT) is used in locally advanced breast cancer to reduce tumour burden prior to surgical resection. However, only a subset of NACT treated patients will respond to treatment or achieve a pathologic complete response (pCR). This multicenter, prospective study (CTRIAL-IE (ICORG) 10-11 study) evaluated circulating microRNA as novel non-invasive prognostic biomarkers of NACT response in breast cancer. Selected circulating microRNAs (Let-7a, miR-21, miR-145, miR-155, miR-195) were quantified from patients undergoing standard of care NACT treatment (n = 114) from whole blood at collected at diagnosis, and the association with NACT response and clinicopathological features evaluated. NACT responders had significantly lower levels of miR-21 (p = 0.036) and miR-195 (p = 0.017), compared to non-responders. Evaluating all breast cancer cases miR-21 was found to be an independent predictor of response (OR 0.538, 95% CI 0.308–0.943, p < 0.05). Luminal cancer NACT responders were found to have significantly decreased levels of miR-145 (p = 0.033) and miR-21 (p = 0.048), compared to non-responders. This study demonstrates the prognostic ability of miR-21, miR-195 and miR-145 as circulating biomarkers stratifying breast cancer patients by NACT response, identifying patients that will derive the maximum benefit from chemotherapy.

Original language	English
Article number	1820
Pages (from-to)	1-12
Number of pages	12
Journal	Cancers
Volume	12
Issue number	7
DOIs	https://doi.org/10.3390/cancers12071820
Publication status	Published - Jul 2020

Keywords

Biomarker
Breast
Chemotherapy
MicroRNA
Neoadjuvant
Prognostic

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/cancers12071820

Cite this

McGuire, A., Casey, M. C., Waldron, R. M., Heneghan, H., Kalinina, O., Holian, E., McDermott, A., Lowery, A. J., Newell, J., Dwyer, R. M., Miller, N., Keane, M., Brown, J. A. L., & Kerin, M. J. (2020). Prospective assessment of systemic microRNAs as markers of response to neoadjuvant chemotherapy in breast cancer. Cancers, 12(7), 1-12. Article 1820. https://doi.org/10.3390/cancers12071820

@article{52f7a188c4d642f0a970feca969da78f,

title = "Prospective assessment of systemic microRNAs as markers of response to neoadjuvant chemotherapy in breast cancer",

abstract = "Neoadjuvant chemotherapy (NACT) is used in locally advanced breast cancer to reduce tumour burden prior to surgical resection. However, only a subset of NACT treated patients will respond to treatment or achieve a pathologic complete response (pCR). This multicenter, prospective study (CTRIAL-IE (ICORG) 10-11 study) evaluated circulating microRNA as novel non-invasive prognostic biomarkers of NACT response in breast cancer. Selected circulating microRNAs (Let-7a, miR-21, miR-145, miR-155, miR-195) were quantified from patients undergoing standard of care NACT treatment (n = 114) from whole blood at collected at diagnosis, and the association with NACT response and clinicopathological features evaluated. NACT responders had significantly lower levels of miR-21 (p = 0.036) and miR-195 (p = 0.017), compared to non-responders. Evaluating all breast cancer cases miR-21 was found to be an independent predictor of response (OR 0.538, 95% CI 0.308–0.943, p < 0.05). Luminal cancer NACT responders were found to have significantly decreased levels of miR-145 (p = 0.033) and miR-21 (p = 0.048), compared to non-responders. This study demonstrates the prognostic ability of miR-21, miR-195 and miR-145 as circulating biomarkers stratifying breast cancer patients by NACT response, identifying patients that will derive the maximum benefit from chemotherapy.",

keywords = "Biomarker, Breast, Chemotherapy, MicroRNA, Neoadjuvant, Prognostic",

author = "Andrew McGuire and Casey, {Maire Caitlin} and Waldron, {Ronan M.} and Helen Heneghan and Olga Kalinina and Emma Holian and Ailbhe McDermott and Lowery, {Aoife J.} and John Newell and Dwyer, {R{\'o}is{\'i}n M.} and Nicola Miller and Maccon Keane and Brown, {James A.L.} and Kerin, {Michael J.}",

note = "Publisher Copyright: {\textcopyright} 2020 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2020",

month = jul,

doi = "10.3390/cancers12071820",

language = "English",

volume = "12",

pages = "1--12",

journal = "Cancers",

issn = "2072-6694",

number = "7",

}

TY - JOUR

T1 - Prospective assessment of systemic microRNAs as markers of response to neoadjuvant chemotherapy in breast cancer

AU - McGuire, Andrew

AU - Casey, Maire Caitlin

AU - Waldron, Ronan M.

AU - Heneghan, Helen

AU - Kalinina, Olga

AU - Holian, Emma

AU - McDermott, Ailbhe

AU - Lowery, Aoife J.

AU - Newell, John

AU - Dwyer, Róisín M.

AU - Miller, Nicola

AU - Keane, Maccon

AU - Brown, James A.L.

AU - Kerin, Michael J.

PY - 2020/7

Y1 - 2020/7

N2 - Neoadjuvant chemotherapy (NACT) is used in locally advanced breast cancer to reduce tumour burden prior to surgical resection. However, only a subset of NACT treated patients will respond to treatment or achieve a pathologic complete response (pCR). This multicenter, prospective study (CTRIAL-IE (ICORG) 10-11 study) evaluated circulating microRNA as novel non-invasive prognostic biomarkers of NACT response in breast cancer. Selected circulating microRNAs (Let-7a, miR-21, miR-145, miR-155, miR-195) were quantified from patients undergoing standard of care NACT treatment (n = 114) from whole blood at collected at diagnosis, and the association with NACT response and clinicopathological features evaluated. NACT responders had significantly lower levels of miR-21 (p = 0.036) and miR-195 (p = 0.017), compared to non-responders. Evaluating all breast cancer cases miR-21 was found to be an independent predictor of response (OR 0.538, 95% CI 0.308–0.943, p < 0.05). Luminal cancer NACT responders were found to have significantly decreased levels of miR-145 (p = 0.033) and miR-21 (p = 0.048), compared to non-responders. This study demonstrates the prognostic ability of miR-21, miR-195 and miR-145 as circulating biomarkers stratifying breast cancer patients by NACT response, identifying patients that will derive the maximum benefit from chemotherapy.

AB - Neoadjuvant chemotherapy (NACT) is used in locally advanced breast cancer to reduce tumour burden prior to surgical resection. However, only a subset of NACT treated patients will respond to treatment or achieve a pathologic complete response (pCR). This multicenter, prospective study (CTRIAL-IE (ICORG) 10-11 study) evaluated circulating microRNA as novel non-invasive prognostic biomarkers of NACT response in breast cancer. Selected circulating microRNAs (Let-7a, miR-21, miR-145, miR-155, miR-195) were quantified from patients undergoing standard of care NACT treatment (n = 114) from whole blood at collected at diagnosis, and the association with NACT response and clinicopathological features evaluated. NACT responders had significantly lower levels of miR-21 (p = 0.036) and miR-195 (p = 0.017), compared to non-responders. Evaluating all breast cancer cases miR-21 was found to be an independent predictor of response (OR 0.538, 95% CI 0.308–0.943, p < 0.05). Luminal cancer NACT responders were found to have significantly decreased levels of miR-145 (p = 0.033) and miR-21 (p = 0.048), compared to non-responders. This study demonstrates the prognostic ability of miR-21, miR-195 and miR-145 as circulating biomarkers stratifying breast cancer patients by NACT response, identifying patients that will derive the maximum benefit from chemotherapy.

KW - Biomarker

KW - Breast

KW - Chemotherapy

KW - MicroRNA

KW - Neoadjuvant

KW - Prognostic

UR - http://www.scopus.com/inward/record.url?scp=85088879891&partnerID=8YFLogxK

U2 - 10.3390/cancers12071820

DO - 10.3390/cancers12071820

M3 - Article

AN - SCOPUS:85088879891

SN - 2072-6694

VL - 12

SP - 1

EP - 12

JO - Cancers

JF - Cancers

IS - 7

M1 - 1820

ER -

Prospective assessment of systemic microRNAs as markers of response to neoadjuvant chemotherapy in breast cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this